Page last updated: 2024-12-09

1-[4-(4-aminophenyl)-1-piperazinyl]ethanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The chemical name **1-[4-(4-aminophenyl)-1-piperazinyl]ethanone** refers to a compound that is commonly known as **N-(4-aminophenyl)piperazine-1-ethanone** or **PAE**.

**Structure and Properties:**

* **PAE** is an organic compound that contains a piperazine ring, an amide group, and an aniline moiety.
* It is a white to off-white solid that is soluble in organic solvents.

**Importance in Research:**

**1. Potential Therapeutic Applications:**

* **Antidepressant activity:** PAE has shown promising antidepressant activity in preclinical studies. It is believed to act as a serotonin and dopamine reuptake inhibitor, similar to other antidepressant medications.
* **Anti-inflammatory activity:** PAE has also demonstrated anti-inflammatory properties in animal models of inflammation. Its mechanism of action may involve modulation of inflammatory signaling pathways.
* **Analgesic activity:** Some studies suggest that PAE may possess analgesic properties, potentially by interfering with pain signaling pathways.

**2. Chemical and Biological Probe:**

* **Synthetic building block:** PAE is a versatile building block for the synthesis of other bioactive compounds. Its functional groups can be modified to create novel molecules with different pharmacological properties.
* **Tool for studying biological targets:** PAE can be used as a tool to study the binding properties and pharmacological effects of specific receptors or enzymes.

**3. Research into Piperazine Derivatives:**

* **Structure-activity relationship studies:** PAE serves as a lead compound for investigating the structure-activity relationship of piperazine derivatives. By modifying its chemical structure, researchers can explore the effects of different functional groups on pharmacological activity.
* **Development of new drugs:** PAE provides a starting point for the development of new drugs targeting various disease conditions.

**Important Note:**

While PAE shows potential therapeutic benefits, it is still in the early stages of research. Extensive preclinical and clinical studies are necessary to determine its safety and efficacy before it can be considered for human use.

**Disclaimer:** I am an AI chatbot and cannot provide medical advice. If you have any questions or concerns about specific medical conditions or treatments, please consult a qualified healthcare professional.

Cross-References

ID SourceID
PubMed CID736269
CHEMBL ID1700038
CHEBI ID92497
SCHEMBL ID188503

Synonyms (48)

Synonym
BB 0244747
1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethano ne
NCGC00182616-01
OPREA1_693361
SDCCGMLS-0064968.P001
TIMTEC1_007041
1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanone
4-(4-acetyl-1-piperazinyl)aniline
92394-00-8
STK029286
1-[4-(4-aminophenyl)piperazin-1-yl]ethanone
HMS1554A01
AKOS000104069
1-(4-(4-aminophenyl)piperazin-1-yl)ethanone
BRD-K28362289-001-01-7
smr001317784
MLS002264484
1-[4-(4-aminophenyl)piperazin-1-yl]ethan-1-one
HMS2213K16
1-(4-(4-aminophenyl)piperazin-1-yl)ethanone;1-acetyl-4-(4-aminophenyl)piperazine
1-acetyl-4-(4-aminophenyl)piperazine
FT-0604244
PS-5341
HMS3356E21
SCHEMBL188503
[4-(4-acetylpiperazin-1-yl)phenyl]amine
1-(4-(4-aminophenyl)piperazin-1-yl)ethan-1-one
4-(4-acetylpiperazin-1-yl) aniline
4-(4-acetylpiperazino)-aniline
AFVUJJNEILZYJQ-UHFFFAOYSA-N
1-acetyl-4-(4-amino-phenyl)piperazine
1-actyl-4-(4-aminophenyl)piperazine
1-[4-(4-amino-phenyl)-piperazin-1-yl]ethanone
4-acetyl-1-(4-aminophenyl)piperazine
4-(4-acetylpiperazin-1-yl)aniline
[4-(4-acetyl-1-piperazinyl)phenyl]amine
mfcd01365904
SY019137
CHEMBL1700038
AC-26278
1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanone, aldrichcpr
DTXSID90352984
CHEBI:92497
1-[4-(4-aminophenyl)-1-piperazinyl]ethanone
Q27164229
1-[4-(4-aminophenyl)piperazino]ethanone
AMY36335
EN300-343896
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485341
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
rac GTPase-activating protein 1 isoform aHomo sapiens (human)IC50 (µMol)16.23007.390057.8904301.2400AID624330
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase 6, apoptosis-related cysteine peptidaseHomo sapiens (human)AC5011.15000.063611.235844.9700AID720632
FAD-linked sulfhydryl oxidase ALRHomo sapiens (human)AC501.05700.00503.212622.7870AID493248
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]